UConn Review Finds 1 Ketamine Infusion Cuts Depression in 4 Hours, Suicidal Thoughts in 24
Updated
Updated · Fox News · May 29
UConn Review Finds 1 Ketamine Infusion Cuts Depression in 4 Hours, Suicidal Thoughts in 24
2 articles · Updated · Fox News · May 29
A review of 26 clinical trials involving more than 1,100 patients found a single intravenous ketamine infusion significantly eased severe depression within four hours and sharply reduced suicidal thoughts within 24 hours.
The JAMA Psychiatry analysis suggests ketamine could fill a critical gap for treatment-resistant patients because standard antidepressants often take weeks, while ketamine acts rapidly through glutamate pathways.
Benefits persisted for about a week for depressive symptoms and up to a month for suicidal thoughts, but the authors said most patients relapsed after one infusion, pointing to a need for repeated sessions.
Temporary side effects—including dissociation, nausea, dizziness and headaches—usually resolved within hours, though researchers and outside psychiatrists said the drug should be given only in closely monitored medical settings because of abuse and safety risks.
The review says ketamine is not FDA-approved for depression but may be used off-label, especially in emergency settings for suicidal patients, while small study sizes and possible placebo unblinding limit how broadly the findings can be applied.
With IV ketamine nearing FDA approval, how can the nation avoid repeating the opioid crisis?
Is the rise of at-home ketamine a breakthrough in access or a dangerous, unregulated experiment?
Ketamine for Severe Depression and Suicidal Crisis: Rapid Relief, Regulatory Breakthroughs, and the Path to Broader Access
Overview
Recent breakthroughs have highlighted ketamine's rapid and effective action for severe depression and suicidal crisis, leading to increased global recognition and pioneering regulatory approvals. These advances mark a paradigm shift in mental health care, emphasizing the urgent need for fast-acting treatments. Research shows that a single intravenous infusion of ketamine can quickly reduce depressive symptoms within hours, though full remission may require further treatment. This rapid response offers immediate relief in emergencies, setting a new standard for addressing acute mental health crises and encouraging broader acceptance and integration of innovative therapies like ketamine.